IL23A and psoriasis: Neutralization of the IL23/TH17 forms the third generation of mAbs established in the clinical routine of moderate-to-sever psoriasis cases, consisting of secukinumab, ixekizumab, and brodalumab, with the latter inhibiting the IL-17R receptor (Figure 1).